Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Grand Pharma (China) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is handled by 1 distinct examiner in 1 distinct art unit. This narrow distribution indicates that the company's current US patent activity is concentrated in a specific technical niche. With only 1 distinct art unit involved, the examiner's specific interpretation of pharmaceutical standards will be the primary factor in the immediate outcome of the portfolio.
DAVID M. SHIM is identified as the busiest examiner with 1 pending office action. This matter constitutes the full extent of the company's current pending workload. For practitioners, the relationship with DAVID M. SHIM is the most critical element of the current prosecution strategy. The lack of multiple pending actions suggests a highly selective filing strategy.
The focus on 1 distinct examiner allows for a response strategy tailored to that individual's past actions. Since there is only 1 pending office action, the company can dedicate resources to ensuring this application meets the requirements of the Biotechnology & Pharmaceuticals area. This centralized prosecution model minimizes the risk of inconsistent arguments across different applications. The involvement of 1 distinct art unit further simplifies the administrative oversight required for this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557598 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING MYOPIA | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557598 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING MYOPIA | SHIM, DAVID M. | 1626 | §103 | Final Rejection | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGrand Pharma (China) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David M. Shim has the most, with 1 of Grand Pharma (China) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
